Enveric Biosciences announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENVB:
- Enveric files for patent AI based computational methods to ID chemicals
- Enveric announces new patent related to EB-373 psilocin prodrug for anxiety
- Enveric Biosciences issued U.S. patent for tryptamine-derive prodrugs
- USPTO issues patent for Enveric’s lead candidate EB-373 to treat anxiety
- Enveric Biosciences completes manufacturing of EB-373 supply drug material